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Boston, MA, USAA B S T R A C TObjective: To review and evaluate published cost-utility analyses
(CUAs) targeting populations in Asia. Methods: We examined
data from the Tufts Medical Center Cost-Effectiveness Analysis
Registry, which contains detailed information on more than 3700
English-language CUAs in peer-reviewed journals through 2012. We
focused on CUAs pertaining to Asian countries (Asian CUAs), sum-
marized study features and methodological practices, and compared
them with CUAs focusing on non-Asian countries (non-Asian
CUAs) from 2000 to 2012. Results: We identiﬁed 175 published CUAs
pertaining to Asian populations (representing 5.1% of all CUAs) from
2000 to 2012. The number has increased from 19 CUAs in the pe-
riod 2000 to 2004 to 107 CUAs in the period 2009 to 2012. Roughly
one-third focused on Japan (33.1%), followed by Taiwan (15.4%),
China (14.9%), and Thailand (8.0%). The diseases targeted in Asian
CUAs were cancer (24.6%), infectious diseases (13.7%), cardiovascular
diseases (8.6%), and musculoskeletal and rheumatological dis-
eases (5.7%). More Asian CUAs evaluated primary prevention
interventions (e.g., vaccinations and screenings) compared withee front matter Copyright & 2015, International S
r Inc.
.1016/j.vhri.2015.02.001
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ndence to: Teja Thorat, 800 Washington Street, Bonon-Asian CUAs (21.7% vs. 16.5%, P ¼ 0.069). Compared with non-
Asian CUAs, signiﬁcantly more studies in Asia suggest that the
health interventions examined provide reasonable value for money.
Asian and non-Asian CUAs did not differ in adherence to good
methodological practices, including clearly stating the perspective,
discounting costs and quality-adjusted life-years, stating a time
horizon, and correctly conducting incremental cost-effectiveness
analysis. Asian CUAs, however, lagged in reporting sensitivity anal-
yses, disclosing funding status, and currency year. Conclusions: The
number of CUAs in Asia has grown steadily, with more than half
focused on pharmaceuticals. The literature reveals that CUAs gen-
erally follow good methodological practices though areas for
improvement exist.
Keywords: Asia, cost-effectiveness, cost-utility analysis, quality-
adjusted life-year.
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Outcomes Research (ISPOR). Published by Elsevier Inc.Introduction
Economic evaluations such as cost-utility analyses (CUAs) and
cost-effectiveness analyses have been widely used by many
developed countries for coverage and reimbursement decisions
[1]. CUAs show the relationship between the resources used
(costs) and the health beneﬁts achieved (measured as quality-
adjusted life-years [QALYs]) for an intervention compared with
an alternative strategy. Because CUAs allow for comparisons
across a broad spectrum of interventions, conditions, and pop-
ulations, such tools are useful to aid health care decision making.
However, in most Asian countries, formal adoption of CUAs
remains in its infancy. Many factors such as lack of relevant
data, resources, expertise, and lack or delayed willingness among
stakeholders and other decision makers to accept economic
evaluation information contribute to the delay in using cost-
effectiveness evidence in health care decision making [2,3].
Over the last decade, rising health care expenditures in Asia
have accelerated the understanding and implementation of
economic evaluations of health care interventions [1,4]. ManyAsian countries are taking steps toward using economic infor-
mation and evidence-based frameworks for health care deci-
sion making [2–4]. For example, in South Korea, the National
Evidence-based Healthcare Collaborating Agency (NECA) has
been set up to review evidence on health economics [1,3–5]. In
Taiwan, the Center of Drug Evaluations reviews health tech-
nology assessments (HTAs) for pricing and reimbursement of
medical technologies [1,3]. Thailand has established the Health
Intervention & Technology Assessment Program for reviewing
evidence on health economics before reimbursement [6]. In
addition, China has established guidance on pharmacoeco-
nomics and currently academic researchers are focusing on
the implementation and utilization of the guidelines [3,6,7].
From 1998 to 2007, the number of published HTA studies in
China has increased from 91 to 421 [8]. The establishment of
the International Society of Pharmacoeconomics and Out-
comes Research Asia Consortium has provided the Asian
countries with a platform to discuss the development and
integration of pharmacoeconomics in health care decision
making [3].ociety for Pharmacoeconomics and Outcomes Research (ISPOR).
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pharmacoeconomics in Asia and predicted increased use of
health economics in the future. To date no systematic review to
our knowledge has examined CUAs targeting Asian populations.
This study will assist in understanding the current landscape of
economic evaluations such as cost-utility studies in Asian coun-
tries, along with providing a valuable portrait of the trends,
quality of studies, and areas for improvement.Methods
The Tufts Medical Center Cost-Effectiveness Analysis Registry
We examined data from the Tufts Medical Center Cost-
Effectiveness Analysis (CEA) Registry (www.cearegisty.org), which
contains detailed information on more than 3700 English-
language CUAs in peer-reviewed journals, with more than
10,300 incremental cost-effectiveness ratios (ICERs) and 14,200
utility weights. Detailed information on the methodology of
literature search and data extraction has been reported else-
where [9,10]. Brieﬂy, we used the keywords “QALYs,” “quality-
adjusted,” and “cost-utility analysis” to search MEDLINE for
English-language publications. Abstracts returned from the
search were screened to deem whether the study contains
original cost-utility analysis. Systematic reviews, editorials,
non-English CUAs, and other studies purely focused on methods
are excluded from the registry.
Two trained reviewers independently reviewed articles that
met the inclusion criteria. The standardized data collection forms
broadly collect data on the methodology, cost-effectiveness
ratios, health utilities, and overall quality of the study. The form
was developed using “checklists” recommended by the Panel on
Cost-Effectiveness in Health and Medicine [11], and other com-
monly adopted guidelines and recommendations on collecting
cost-effectiveness information [12,13]. Reviewers received a man-
ual entailing the details of the review process to maintain
uniformity in the data collected.
The data collection forms are used to collect data over 40
variables pertaining to study sponsorship, discounting, time
horizon, sensitivity analyses, target population along with the
intervention and comparator, ICERs, and health utilities from
published CUAs. CEA registry reviewers also assign a subjective
quality score for each article (from 1 [low] to 7 [high]), which is
based on factors such as whether articles present a correct
computation of the ICERs, a comprehensive characterization of
uncertainty, an explicit speciﬁcation of assumptions, and an
appropriate and explicit estimation of utility weights. ICERs were
expressed as 2013 US dollars per QALY using exchange rates forLiterature search using keywords like 
“QALYs”, “quality-adjusted” and 
“cost-utility analysis”
Abstract screening
Article review & Data collection
Tufts CEA Registry
3,772 CUAs published from 1976-2012
- 17
- 48
- 66
ig. 1 – Search strategy and sample selection process. CEA, cost-
ncremental cost-effectiveness ratios; QALY, quality-adjusted lifecurrency conversion and the consumer price index to adjust for
inﬂation.
Sample Selection and Data Analysis
We identiﬁed English-language CUAs pertaining to Asian coun-
tries (Asian CUAs) published from 2000 through 2012 and sum-
marized key study features such as country of study, study
sponsorship, author afﬁliation, disease category, perspective,
discount rate, prevention stage, and quality scores. Fig. 1 presents
the search strategy and sample selection process along with a
consort diagram. To evaluate their adherence to methodological
standards in the ﬁeld, we reported the proportion of Asian CUAs
that 1) clearly state the study perspective, 2) discount costs and
QALYs, 3) clearly state the time horizon for the analysis, 4) state
the year of currency for the reported cost-effectiveness ratios, 5)
disclose the study funder, 6) correctly conduct the ICER calcu-
lation, 7) include acceptability curves, and 8) state whether the
study performed sensitivity analyses including the types of
sensitivity analyses. These criteria for determining adherence to
methodological and reporting practices were based on published
recommendations [13,14].
We used the chi-square test to compare Asian CUAs with
CUAs from all other countries (non-Asian CUAs) with respect to
adherence to good methodological practices, average quality
scores, and the distribution of ICERs (as expressed as $2013/
QALY). We also compared the proportion of studies that report
high-value and low-value services in Asian and non-Asian CUAs.
“High-value” services were deﬁned as cost-saving interventions
(improved health and decreased health costs) and interventions
with an ICER of less than $50,000/QALY; “low-value” services
were deﬁned as dominated interventions (increased costs and
worsened health) and interventions with an ICER of more than
$100,000/QALY. ICERs for interventions with lower costs and
lower QALYs were excluded from this sample (n ¼ 127). All
statistical analyses were performed using SAS 9.3 software
(SAS, Cary, NC).Results
Of the 3414 CUAs published from 2000 to 2012, 175 (5.1%)
pertained to Asian countries and contained 483 ICERs and 667
utility weights. The number of published Asian CUAs has
increased over the past decade, from 19 CUAs in the period
2000 to 2004 to 107 CUAs in the period 2009 to 2012. Roughly one-
third of the CUAs focused on Japan (n ¼ 58, 33.1%), followed by
Taiwan (n ¼ 27, 15.4%), China (n ¼ 26, 14.9%), Thailand (n ¼ 14,
8.0%), and South Korea (n ¼ 12, 6.9%) (Fig. 2). A total of 32393,414 CUAs published from 2000-2012
Asian CUAs
5 CUAs
3 ICERs
7 utility weights
Non-Asian CUAs
- 3,239 CUAs
- 8,769 ICERs
- 12,180 utility weights
effectiveness analysis; CUA, cost-utility analysis; ICERs,
-year.
Japan, 33.1%
Taiwan, 15.4%
China, 14.9%
Thailand, 8.0%
South Korea, 6.9%
Singapore, 6.3%
Hong Kong, 5.1%
India, 4.0%
Iran, 2.3% 
Vietnam, 
2.3%
Other (Bangladesh, 
Malaysia, 
Indonesia), 2.9%
Fig. 2 – Asian cost-utility analyses by country of study (2000–2012). (Two studies pertain to more than one country.)
V A L U E I N H E A L T H R E G I O N A L I S S U E S 6 C ( 2 0 1 5 ) 7 – 1 3 9(94.9%) CUAs focused on non-Asian countries. The non-Asian
CUAs were most often set in the United States (40%), followed by
the United Kingdom (9%), Canada (8%) and The Netherlands (7%).
Most interventions focused on pharmaceuticals (56.0%), fol-
lowed by screening programs (19.4%), immunizations (12.0%),
surgical interventions (9.1%), diagnostic tests (9.1%), and medical
procedures (6.9%) (Fig. 3). Table 1 presents information on the
characteristics and methodological practices among published
Asian and non-Asian CUAs. Author afﬁliation in the published
Asian CUAs was predominantly academic (90.9%) (Table 1). A
total of 62.9% of the studies targeted tertiary prevention (i.e.,
interventions aimed at reducing complications and progression
of established disease). Most of the studies were funded by
government agencies (29.1%), followed by pharmaceutical and
device companies (21.7%), foundations (6.3%), and health care
organizations (2.9%). A total of 28.0% of the CUAs did not report a
funding source. Asian CUAs examined diverse disease areas, with
many focused on cancer (24.6%), infectious diseases (13.7%), and
cardiovascular diseases (8.6%). Most of the Asian CUAs applied a
health care perspective (69.1%) followed by societal perspective
(27.4%) to their economic analyses. For discounting costs and
QALYs, Asian CUAs mainly used a discount rate of 3% or 5%
(57.1% and 10.3%, respectively).56.0%
19.4%
12.0%
9.1% 9.1%
0%
10%
20%
30%
40%
50%
60%
Fig. 3 – Asian cost-utility analyses by intervention type (2000–20
Medical procedure is deﬁned as a nonsurgical, nondiagnostic pr
development of a facility or the distribution of personnel.Compared with non-Asian CUAs, fewer Asian CUAs were
sponsored by pharmaceutical and device companies (21.7% vs.
33.3%, P ¼ 0.001) (Table 1). Also, a signiﬁcantly higher proportion
of Asian CUAs reported no funding compared with non-Asian
CUAs (10.9% vs. 5.8%, P ¼ 0.0068) (Table 1). In terms of disease
areas researched, Asian CUAs were more likely to examine
cancer (24.6% vs. 13.5%, P o 0.001) and less likely to examine
musculoskeletal and rheumatological diseases (5.7% vs. 9.9%, P ¼
0.07), cardiovascular diseases (8.6% vs. 17.0%, P ¼ 0.0035), and
digestive diseases (1.7% vs. 4.4%, P ¼ 0.08) compared with non-
Asian CUAs. Also, more Asian CUAs evaluated primary preven-
tion interventions (e.g., vaccinations and screenings) as com-
pared with non-Asian CUAs (21.7% vs. 16.5%, P ¼ 0.07).
Asian and non-Asian CUAs did not differ in adherence to good
methodological practices: clearly stating the perspective (85.1%
vs. 87.5%, P ¼ 0.37); discounting costs and QALYs (84.0% vs. 85.8%,
P ¼ 0.51); stating a time horizon for the analysis (86.3% vs. 89.9%,
P ¼ 0.13); including acceptability curves (36.0% vs. 36.0%, P ¼ 0.80),
and correctly conducting incremental CEA (83.4% vs. 79.6%, P ¼
0.22) (Table 1). Asian CUAs, however, were less likely than non-
Asian CUAs to disclose their funding source (72.0% vs. 82.9%, P o
0.001) and the year of currency (69.1% vs. 86.0%, P o 0.0001), and
perform sensitivity analyses (92.3% vs. 96.0%, P ¼ 0.03). Compared6.9% 6.9% 5.7%
2.9% 3.4%
12). (Intervention categories are not mutually exclusive.)
ocedure. Care delivery refers to interventions aimed at the
Table 1 – Characteristics and methodological practices among published Asian and non-Asian cost-utility
analyses (2000–2012).
Characteristic Asian countries (N ¼ 175) Non-Asian countries (N ¼ 3239) P value
Author afﬁliation*
Academic 159 (90.9) 2852 (88.1) 0.2626
Health care organization 66 (37.7) 1170 (36.1) 0.6695
Government 31 (17.7) 505 (15.6) 0.4521
Pharmaceutical industry† 22 (12.6) 707 (21.8) 0.0036
Consultant/contract† 12 (6.9) 705 (21.8) o0.0001
Other 3 (1.7) 76 (2.3) 0.588
Prevention stage
Primary‡ 38 (21.7) 533 (16.5) 0.0694
Secondary 27 (15.4) 631 (19.5) 0.1855
Tertiary 110 (62.9) 2075 (64.1) 0.7462
Funding source
Government§ 51 (29.1) 1188 (36.7) 0.0435
Pharmaceutical/device† 38 (21.7) 1079 (33.3) 0.0014
Foundation‡ 11 (6.3) 355 (11.0) 0.0515
Health care organization 5 (2.9) 129 (4.0) 0.4551
Other 20 (11.4) 258 (8.0) 0.1028
None† 19 (10.9) 189 (5.8) 0.0068
Not determined† 49 (28.0) 555 (17.1) 0.0002
Disease category
Cancer† 43 (24.6) 437 (13.5) o0.0001
Infectious 24 (13.7) 323 (10.0) 0.1106
Cardiovascular† 15 (8.6) 551 (17.0) 0.0035
Neuropsychiatric 12 (6.9) 293 (9.0) 0.3228
Endocrine 12 (6.9) 215 (6.6) 0.9097
Musculoskeletal and rheumatologic‡ 10 (5.7) 322 (9.9) 0.066
Genitourinary 8 (4.6) 122 (3.8) 0.5879
Respiratory 6 (3.4) 98 (3.0) 0.7626
Digestive‡ 3 (1.7) 144 (4.4) 0.0829
Other 36 (23.2) 706 (22.8) 0.9038
Perspective
Societal 48 (27.4) 817 (25.2) 0.5137
Health care payer 121 (69.1) 2346 (72.4) 0.3442
Other 3 (1.7) 29 (0.9) 0.2735
Not stated 3 (1.7) 47 (1.5) 0.777
Discounting
3%† 100 (57.1) 1394 (43.0) 0.0002
5% 18 (10.3) 239 (7.4) 0.1557
Other† 50 (28.6) 1512 (46.7) o0.0001
None 7 (4.0) 94 (2.9) 0.4038
Methods and quality
Clearly stated perspective 149 (85.1) 2833 (87.5) 0.3681
Discounted costs and QALYs 147 (84.0) 2779 (85.8) 0.508
Stated the time horizon 151 (86.3) 2910 (89.9) 0.1288
Stated the year of currency† 121 (69.1) 2774 (86.0) o0.0001
Disclosed study funding† 126 (72.0) 2683 (82.9) 0.0002
Performed sensitivity analyses§ 162 (92.3) 3110 (96.0) 0.0262
Performed univariate sensitivity analysis§ 91 (52.0) 1955 (60.4) 0.028
Performed probabilistic sensitivity analysis§ 86 (49.1) 1839 (57.8) 0.0473
Conducted incremental analysis correctly 146 (83.4) 2578 (79.6) 0.2184
Included acceptability curves 63 (36.0) 1167 (36.0) 0.8048
Average quality score, mean  SD (95% CI)‡ 4.27  1.0812 (4.1044– 4.4270) 4.49  0.9818 (4.4608– 4.5284) 0.0663
The χ2 test was used to calculate P values. Values are n (%) unless indicated otherwise.
CI, conﬁdence interval; QALY, quality-adjusted life-year.
* Each study can be assigned more than one category; as a result, the proportions sum to more than 100%.
† P o 0.01.
‡ P o 0.1.
§ P o 0.05.
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performed probabilistic and univariate sensitivity analyses
(57.8% vs. 49.1%, P ¼ 0.05, and 60.4% vs. 52%, P ¼ 0.03, respec-
tively). The average quality score of Asian CUAs was modestly
lower than that of non-Asian CUAs (4.27 vs. 4.49, P ¼ 0.067)
(Table 1).
The median ICER for Asian CUAs was signiﬁcantly lower than
that for non-Asian studies ($9,800/QALY vs. $21,000/QALY, P ¼
0.0597). Asian CUAs report a signiﬁcantly high proportion of
interventions that were classiﬁed as high-value services (73.8%
vs. 65.9%, P o 0.01), namely, cost-saving interventions and
interventions with an ICER of less than $50,000/QALY, and a
low proportion of interventions that were classiﬁed as low-value
services (16.1% vs. 23.0%, P o 0.01), namely, dominated inter-
ventions and interventions with an ICER of more than $100,000/
QALY, compared with non-Asian CUAs (Fig. 4).Discussion
More than 170 English-language CUAs targeting population in
Asian countries were published from 2000 through 2012, and the
number steadily increased over time. We found that the CUAs
were funded mainly by nonindustry sources, which seems to
reﬂect the increasing participation of government agencies and
health care organizations in health care decision making.
Roughly 63% of Asian CUAs were targeted toward treatments as
compared with primary and secondary prevention interventions.
A higher proportion of primary prevention interventions among
Asian CUAs, such as mass immunization programs and disease-
speciﬁc screening, than among non-Asian CUAs can be attributed
to a high prevalence of communicable diseases or the growing
importance of prevention initiatives in Asian countries. More
than half of the interventions were focused on pharmaceuticals,
followed by screening, immunization, and surgical interventions.
Researchers have devoted their attention to diseases such as
cancer and infectious diseases, followed by cardiovascular18.2%
39.0%
16.4%17.9%
28.1%
19.5%
Cost-saving <$20,000*** $20,000 -
$50,000*
Asian CUAs
(n=477)
N
(
High value services
Asian CUAs- 73.8%,
Non-Asian CUAs- 65.9%
(p<0.01)
Fig. 4 – Distribution of incremental cost-effectiveness ratios (ICE
2012). ICERs are in 2013 US dollars (2013US $). CUA, cost-utility
0.05; *P o 0.1.diseases, neuropsychiatric diseases, endocrine disorders, and
musculoskeletal and rheumatologic diseases. Also, compared
with non-Asian CUAs, Asian CUAs have published signiﬁcantly
more on cancer-focused interventions. Our analysis showed
encouraging evidence for adherence of Asian CUAs to recom-
mended methodological and reporting practices. No signiﬁcant
differences were reported between Asian and non-Asian CUAs in
the following areas: clearly stating the perspective, discounting
costs and QALYs, stating the time horizon, including cost-
effectiveness acceptability curves, and calculating incremental
analysis correctly. Overall, the CUAs targeted toward the Asian
population generally observed good methodological practices,
though the average quality score was modestly lower than the
overall mean. We identiﬁed, however, a few areas of improve-
ment among Asian CUAs. Asian CUAs lagged in performing
sensitivity analyses, disclosing their funding source, and report-
ing the year of currency used in estimating the cost-effectiveness
ratios. Sensitivity analysis is a critical component of a CEA that
demonstrates the impact of parameter uncertainty on the out-
comes [15]. Transparency of the study can be improved by
disclosing the funding source and stating the year of currency,
allowing for the better interpretation of results. On comparing the
distributions of cost-effectiveness ratios of Asian and non-Asian
CUAs, we found that signiﬁcantly higher proportions of ratios
from Asian CUAs had a favorable cost-effectiveness value, rep-
resenting good value for money. We found that the median ICER
for Asian CUAs was signiﬁcantly lower than the median ICER for
non-Asian CUAs. This might, in part, be attributed to lower
health care costs in Asian countries than in developed Western
countries [16]. Future research on understanding the variation in
cost-effectiveness ratio for the same intervention between Asian
and non-Asian CUAs will be worthwhile.
The growing number of Asian CUAs reﬂects the increasing
need for understanding the costs of health care interventions
relative to the beneﬁts gained. To our knowledge, this is the ﬁrst
study that systematically reviewed CUAs pertaining to Asian
populations. Our results highlight the trends, characteristics,10.9% 10.1%
5.5%
12.0%
14.8%
7.6%
$50,000 -
$100,000
>$100,000** Dominated*
on-Asian CUAs
n=8,627)
Low value services
Asian CUAs- 16.1%,
Non-Asian CUAs- 23.0%
(p<0.01)
Rs) among Asian and non-Asian cost-utility analyses (2000–
analysis; QALY, quality-adjusted life-year. ***P o 0.01; **P o
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proportion of cost-effective interventions, and quality of eco-
nomic evaluations in Asian CUAs. This study also compared the
methodological characteristics and distribution of ICERs in Asian
and non-Asian CUAs, thereby assisting the development of
research among Asian studies by highlighting the areas of
improvement in methodological and reporting practices. One
way to improve study quality is by emphasizing the need for
journals, especially those with little experience in publishing
CUAs, to follow checklists and guidelines to authors, editors, and
peer reviewers to increase the quality of reporting analysis and
results [17,18]. Adherence to the available set of methodological
guidelines can allow for transparency in methods and analysis,
ultimately improving the study quality.
Asian countries spent 4.5% of their gross domestic product on
health expenditures in 2010 [19]. The total health expenditure as
a share of the gross domestic product has increased for most of
the Asian countries in the last 5 years [19]. The average share of
pharmaceutical spending in Asian countries is approximately
double than the share of Organisation for Economic Co-operation
and Development countries (29% vs. 15.6%) [19,20]. Escalating
costs of drugs, increasing population, and increasing need for
medications or other health interventions has put a huge burden
on devising methods of cost-containment in Asian countries.
Some of the Asian countries have already started to use cost-
effectiveness evidence in the management of medical interven-
tions for reimbursement decision making. CUAs evaluating dif-
ferent medical interventions have been incorporated in HTAs in
several Asian countries. HTA is a tool used by health care
decision makers, regulatory agencies, and health care providers
while assessing medical technologies. HTAs help inform pricing
and reimbursement decisions, provide cost-containment options,
present clinical and economic value of interventions, and assist
health care providers to make decisions on the management of
medical technology. The health technology assessment land-
scape is rapidly changing in the Asian countries. For example,
the Medical Service Act in Korea requires the submission of cost-
effectiveness evidence for drugs and other medical technologies
for reimbursement. Several agencies such as the Committee for
New Health Technology Assessment and NECA have been set up
for research and approval in South Korea [1,4]. The South Korean
reimbursement system consists of NECA that initiates research
and provides information on economic evaluations for review to
Health Insurance Review and Assessment Services and a con-
sequent reimbursement decision is made by the Ministry of
Health and Welfare [1,3–5]. Thailand has also set up the Health
Intervention & Technology Assessment Program to promote
decision making through economic evaluations of health tech-
nologies [6]. Likewise, agencies have been set up in other Asian
countries to provide information on the value of heath technol-
ogies to assist better decision making, namely, the HTA division
within the Center for Drug Evaluation in Taiwan, the HTA section
within the Ministry of Health in Malaysia, and the HTA branch
within the Ministry of Health in Singapore [1,21,22]. Similar
efforts are being made in Indonesia, China, Philippines, and Laos.
Currently, China has published guidelines on pharmacoeconom-
ics, which are expected to be recommended and widely adopted
in a few years [3,7,23]. The guidelines mention the inclusion of
CUAs along with other types of economic evaluations [7].
Increasing number of pharmaceutical companies in China have
started promoting the use of pharmacoeconomics for making
decisions regarding reimbursement and pricing [24]. The Ministry
of Health in Japan is undertaking a pilot program to develop HTA
guidelines and to understand the integration of the program in
the current reimbursement system [3]. In spite of having an early
understanding of the need and value of pharmacoeconomics,
Japan has lagged in implementing the widespread use of cost-effectiveness research [24]. The understanding and uptake of
economic evaluations and HTAs has been slower in countries
such as Bangladesh, Bhutan, Brunei, Cambodia, India, and Paki-
stan [1]. As seen in the examples above, some countries require
pharmacoeconomic information for approval and reimbursement
while some countries only recommend the submission of data by
pharmaceutical companies [2]. Evidence indicates that pharma-
coeconomic methods are likely to be adopted and we can expect
to see an incorporation of cost-effectiveness evidence in the
regulatory system to control wastage and promote effective use
of technologies [25]. We presume that the need for evidence-
based decision making in Asian countries for better allocation of
resources to cost-effective treatments will provide a boost to the
number of CUAs published. However, the uptake and functioning
of HTA agencies and review and approval committees is subject
to the underlying politics, culture, history, and health care
framework of the country [26]. Our study does not evaluate the
quality of CUAs on the basis of the presence of an HTA agency in
the region. Future research could focus on comparing the quality
of CUAs from Asian countries with established HTA agencies to
those without HTA agencies
There are a few noteworthy limitations to this study. First, the
CEA registry only includes English-language articles that presented
original cost-utility estimate. CUAs published in non-English lan-
guages were not reviewed. Also, our review was restricted to
economic evaluations that measure health beneﬁts in terms of
QALYs; other end points such as life-years were not included.
Second, the quality score evaluated in this study was based on a
subjective seven-point Likert scale provided by two CEA registry
reviewers. The score is highly correlated with study methodology
details such as correctly conducting incremental analyses, reporting
sensitivity analyses, including cost-effectiveness acceptability
curves, and estimating utility weight [27]. However, although the
scale has been recognized and adopted in other publications, it
might be subject to reviewer bias and might not effectively capture
the nuances in clinical and model assumptions and minute quality
differences. Third, comparators used for determining the ICERs
were not judged for their appropriateness or relevancy. Fourth, our
results might be subject to publication bias because published CUAs
often tend to report positive or favorable ratios [28]. Fifth, for
deﬁning high-value and low-value services, we used widely
accepted cost-effectiveness thresholds of US $50,000 and US
$100,000/QALY; however, these thresholds may not correctly reﬂect
value for money provided in individual Asian countries.
In conclusion, we found that the number of CUAs focused on
the Asian population has rapidly increased in the past few years.
By summarizing and analyzing the articles over a 13-year period,
we found few differences in the quality of CUAs targeted toward
Asian and non-Asian populations. The information summarized
in this study provides a quick look at the trends in published
Asian CUAs along with highlighting the areas of improvement.
The areas of improvement include disclosing funding status,
reporting the currency year used in the analysis, and performing
sensitivity analyses, especially probabilistic sensitivity analyses.
The fast growing ﬁeld of pharmacoeconomics in Asia identiﬁes
an increasing number of economic evaluations on pharmaceut-
ical products and in disease areas such as cancer, infectious
diseases, and cardiovascular diseases. This study highlights the
growing interest among emerging markets in certain Asian
countries to understand and implement economic evaluations
for health care decision making.Acknowledgments
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